SOFYA PINTOVA

Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology NEW YORK, NY NPI 1760737720

General Payments — all program years on this page

$57,471.03

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 81
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $7,944.62 across 17 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $5,194.9810
Merck Sharp & Dohme Corporation $2,730.006
ARRAY BIOPHARMA INC $19.641

By program year

Program yearAmountRecords
2018 $3,110.667
2019 $4,946.0514
2022 $8,989.2314
2023 $32,480.4729
2024 $7,944.6217

Records — PY2024 (17)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1104291602 AstraZeneca Pharmaceuticals LP $109.54 10/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104371807 AstraZeneca Pharmaceuticals LP $2,740.00 06/16/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1104504382 AstraZeneca Pharmaceuticals LP $23.67 08/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104508778 AstraZeneca Pharmaceuticals LP $19.01 07/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104614942 AstraZeneca Pharmaceuticals LP $22.96 03/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104682149 AstraZeneca Pharmaceuticals LP $15.28 09/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105218722 AstraZeneca Pharmaceuticals LP $300.00 10/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1105338128 AstraZeneca Pharmaceuticals LP $24.52 06/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105482263 AstraZeneca Pharmaceuticals LP $1,640.00 11/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1105673155 AstraZeneca Pharmaceuticals LP $300.00 12/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1131197423 ARRAY BIOPHARMA INC $19.64 02/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141583397 Merck Sharp & Dohme LLC $682.50 06/19/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141684937 Merck Sharp & Dohme LLC $227.50 02/28/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141684939 Merck Sharp & Dohme LLC $455.00 01/08/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141685061 Merck Sharp & Dohme LLC $455.00 04/03/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141830434 Merck Sharp & Dohme LLC $455.00 04/22/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141863541 Merck Sharp & Dohme LLC $455.00 02/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.